2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethanone
RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.